Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
136 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape. Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 3, 1, 23, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy (Toxicology). - The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Chemotherapy Induced Peripheral Neuropathy - Overview Chemotherapy Induced Peripheral Neuropathy - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development Achelios Therapeutics Inc Advinus Therapeutics Ltd Apollo Endosurgery Inc Aptinyx Inc Asahi Kasei Pharma Corp Can-Fite BioPharma Ltd Celgene Corp Eisai Co Ltd Immune Pharmaceuticals Inc Insys Therapeutics Inc Kineta Inc KPI Therapeutics Inc Krenitsky Pharmaceuticals Inc Midatech Pharma US Inc Mundipharma International Ltd Nemus Bioscience Inc Neurocentrx Pharma Ltd Panacea Pharmaceuticals Inc PeriphaGen Inc PledPharma AB Sova Pharmaceuticals Inc Trevena Inc WEX Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy - Drug Profiles (amitriptyline + ketamine hydrochloride) - Drug Profile Product Description Mechanism Of Action R&D Progress ACY-1083 - Drug Profile Product Description Mechanism Of Action R&D Progress AM-1710 - Drug Profile Product Description Mechanism Of Action R&D Progress APX-2009 - Drug Profile Product Description Mechanism Of Action R&D Progress APX-3330 - Drug Profile Product Description Mechanism Of Action R&D Progress BR-297 - Drug Profile Product Description Mechanism Of Action R&D Progress cannabidiol - Drug Profile Product Description Mechanism Of Action R&D Progress dimiracetam - Drug Profile Product Description Mechanism Of Action R&D Progress Drugs for Chemotherapy Induced Peripheral Neuropathy and Neurology - Drug Profile Product Description Mechanism Of Action R&D Progress Drugs for Peripheral Neuropathy - Drug Profile Product Description Mechanism Of Action R&D Progress DX-0332 - Drug Profile Product Description Mechanism Of Action R&D Progress E-2072 - Drug Profile Product Description Mechanism Of Action R&D Progress HM-01 - Drug Profile Product Description Mechanism Of Action R&D Progress KCP-400 - Drug Profile Product Description Mechanism Of Action R&D Progress ketoprofen - Drug Profile Product Description Mechanism Of Action R&D Progress KP-544 - Drug Profile Product Description Mechanism Of Action R&D Progress KRN-5500 - Drug Profile Product Description Mechanism Of Action R&D Progress LM-11A31BHS - Drug Profile Product Description Mechanism Of Action R&D Progress Lpathomab - Drug Profile Product Description Mechanism Of Action R&D Progress MR-309 - Drug Profile Product Description Mechanism Of Action R&D Progress NB-2111 - Drug Profile Product Description Mechanism Of Action R&D Progress NB-2222 - Drug Profile Product Description Mechanism Of Action R&D Progress NRX-2922 - Drug Profile Product Description Mechanism Of Action R&D Progress NT-24336 - Drug Profile Product Description Mechanism Of Action R&D Progress PAN-811 - Drug Profile Product Description Mechanism Of Action R&D Progress PGN-503 - Drug Profile Product Description Mechanism Of Action R&D Progress piclidenoson - Drug Profile Product Description Mechanism Of Action R&D Progress pirenzepine hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress PP-095 - Drug Profile Product Description Mechanism Of Action R&D Progress Q-201 - Drug Profile Product Description Mechanism Of Action R&D Progress ricolinostat - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit Cystathionine Gamma Lyase for Inflammatory Pain and Chemotherapy Induced Peripheral Neuropathy - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Chemotherapy Induced Peripheral Neuropathy - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Pain - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Block Nav 1.8 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Target S1PR for Central Nervous System and Toxicology - Drug Profile Product Description Mechanism Of Action R&D Progress Tetrodotoxin - Drug Profile Product Description Mechanism Of Action R&D Progress thrombomodulin alfa - Drug Profile Product Description Mechanism Of Action R&D Progress U-2902 - Drug Profile Product Description Mechanism Of Action R&D Progress XT-150 - Drug Profile Product Description Mechanism Of Action R&D Progress ZF-198 - Drug Profile Product Description Mechanism Of Action R&D Progress Chemotherapy Induced Peripheral Neuropathy - Dormant Projects Chemotherapy Induced Peripheral Neuropathy - Discontinued Products Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones Featured News & Press Releases Aug 02, 2017: Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference Jul 13, 2017: Apexian Pharmaceuticals Announces FDA Agreement For Inclusion of Chemotherapy Induced Peripheral Neuropathy (CIPN) Indication Under Currently Approved IND Jun 29, 2017: PledPharma strengthens the management team with a Vice President Product Strategy and Development Mar 08, 2017: Regenacy Pharmaceuticals Demonstrates Reversal of Chemotherapy-Induced Peripheral Neuropathy with HDAC6 Inhibitor Ricolinostat in Preclinical Model Dec 01, 2016: Nemus Bioscience Announces Milestones In The Development Of Fully Synthetic Clinical-Grade Active Pharmaceutical Ingredient For Drug Candidate NB2111 And Formulation Contract With AMRI And Catalent Pharma Solutions Jun 02, 2016: NEMUS Bioscience Identifies Unique Cannabidiol Derivative as a Lead Candidate in Its Neuropathy-Related Pain Management Program May 19, 2016: PledPharma to present the Phase IIb PLIANT study data at ASCO 2016 May 17, 2015: Wex Pharmaceuticals Announces Presentation Of Preclinical Data On Chemotherapy-Induced Peripheral Neuropathy And Burn Injury Pain At The 2015 American Pain Society Conference On Its Lead Compound, Halneuron (TTX) Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program Apr 10, 2012: EpiCept's AmiKet Receives Fast Track Designation From FDA Feb 07, 2012: EpiCept Files For AmiKet Fast Track Designation Dec 23, 2011: EpiCept Receives FDA Permission To Initiate AmiKet Phase III Clinical Development Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Advinus Therapeutics Ltd, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Apollo Endosurgery Inc, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aptinyx Inc, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Asahi Kasei Pharma Corp, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Can-Fite BioPharma Ltd, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Celgene Corp, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Eisai Co Ltd, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Insys Therapeutics Inc, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kineta Inc, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by KPI Therapeutics Inc, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Krenitsky Pharmaceuticals Inc, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Midatech Pharma US Inc, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mundipharma International Ltd, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Nemus Bioscience Inc, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Neurocentrx Pharma Ltd, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Panacea Pharmaceuticals Inc, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by PeriphaGen Inc, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by PledPharma AB, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sova Pharmaceuticals Inc, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Trevena Inc, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Pipeline by WEX Pharmaceuticals Inc, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H2 2017 Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H2 2017 (Contd..1), H2 2017 Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
